Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Shares of Johnson & Johnson ( JNJ -6.57%) are tumbling on Tuesday. The company's stock lost 6.3% as of 2:25 p.m. ET. The drop ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

Johnson & Johnson’s plan to settle thousands of talc-related lawsuits through bankruptcy was shot down in court.

A U.S. bankruptcy judge ruled against the company's attempt to settle tens of thousands of claims alleging its talc products ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

A Houston bankruptcy judge has rejected Johnson & Johnson’s to use federal bankruptcy procedures to force a settlement with ...

A judge rejected Johnson & Johnson’s $10 billion proposal to end tens of thousands of lawsuits alleging that its products ...

A U.S. bankruptcy court judge has denied Johnson & Johnson’s settlement plan related to baby powder containing talc, ...

Kunle Odunsi has been named the speaker for the University of Chicago’s Convocation ceremony on June 7. A renowned expert in ...